Paper Form - Md Anderson Cancer Center: Fill & Download for Free

Yes. People don't understand it and we don't have good measurement metrics so they tend to say no and call it placebo. Or otherwise malign it. They get very angry at it too.Here's part of an interesting article about a collaboration between mainstream med center and Indian researchers:"Dr Sen Pathak, professor of cell biology and genetics at the University of Texas MD Anderson Cancer Center (MDACC) in Houston, approached the Banerjis and, together, they set up a trial to test two homeopathic remedies, Ruta 6 and Calcarea Phosphorica 3X, on 15 patients with brain tumours. Six of the seven patients with gliomas, a type of brain cancer, had complete regression. In an accompanying in vitro laboratory study, scientists noticed that the remedies induced death-signalling pathways in the cancer cells (Int J Oncol, 2003; 23: 97582).The result is astonishing. Gliomas are considered to be incurable; of 10,000 people diagnosed with malignant gliomas each year in the US alone, only around half are alive a year later, and just 25 per cent two years later (The Washington Post, 20 May 2008).The scientists at MDAnderson CC were so impressed by the results that they started to offer homeopathic remedies as part of their range of cancer treatments.In 1999, the US governments National Cancer Institute (NCI) independently evaluated the Banerji Protocol on 10 patients with different kinds of cancers. In four cases of lung and oesophageal cancer, the NCI researchers confirmed that there had been partial responses to the homeopathic remedies. None of the patients had received any previous conventional cancer treatment.The NCI concluded that there was sufficient evidence of efficacy to support further research into the protocol, an historic decision as it marked the first time that any official health institute in the US had worked with an alternative therapy for cancer treatment (Oncol Rep, 2008; 20: 6974).In the laboratoryTo understand the mechanism of the homeopathic remedies on cancer cells, eight scientists from MDACC tested four remedies, Carcinosin 30C, Conium Maculatum 3C, Phytolacca Decandra 200C and Thuja Occidentalis 30C on two human breast-cancer cell lines. Around 5000 cells were exposed to the remedies and to a placebo, the solvent without the active ingredients of the remedies, for periods of between one and four days. The experiment was repeated three times.Two of the remedies, Carcinosin and Phytolacca, achieved up to an 80 per cent response, indicating that they caused apoptosis, or cell death. By comparison, the placebo solvent achieved only a 30 per cent reduction, suggesting that the effect was more than twice that of the placebo.Also, the effect was strongest with the greater dilution which, in the contrary world of homeopathic medicine, means more powerful and for longer periods of exposure.The remedies triggered an apoptotic cascade that interfered with the cancer cells normal growth cycle and, yet, the surrounding healthy cells were untouched, the researchers found. In other words, they targeted only the cancer cells, whereas chemo-therapy drugs attack all growing cells. And, say the researchers, the effects of Carcinosin and Phytolacca were as powerful as Taxol (paclitaxel), the most commonly prescribed chemother-apy drug for breast cancer (Int J Oncol, 2010; 36: 395403).Rooting for RutaAlthough Carcinosin and Phytolacca fared well in the laboratory, many of the Foundations patients are taking the Ruta 6 remedy and with extraordinary success, according to one survey of 127 American patients with brain tumours, half of whom were at grade IV, the end-stage before death.The tumours had completely disappeared, according to magnetic resonance imaging (MRI) scans, in 18 of the 127 patients who were taking only Ruta and no conventional treatment. Another nine patients had significant tumour regression. The tumours were stable in around half of all patients scanned, but had grown in around 27 patients. Overall, around 79 per cent of the brain-tumour patients surveyed saw either great or some benefit from Ruta.In an earlier study by the Foundation among patients who were taking Ruta alongside conventional chemotherapy for brain tumours, 72 per cent derived some or great benefit from Ruta and chemotherapy combined, suggesting that Ruta on its own is more effective than, or certainly as effective as, the drug, and without its debilitating side-effects (http://health.groups.yahoo.com/group/Ruta6).In a separate study of brain-tumour cases, 148 patients with malignant gliomas and 144 with meningiomas treated at the Foundation between 1996 and 2001, the 91 patients who had been treated exclusively with Ruta and Calc Phos had an average survival time of 92 months, whereas 11 patients who had been treated conventionally, and used homeopathy as a supplement, survived for 20 months. In addition, 7 per cent of the homeopathy-only patients had a complete cure, 60 per cent were improved, 22 per cent were stable with the cancer neither improving nor worsening and 11 per cent saw their cancer worsen, or die (Prasanta Banerji Homeopathic Research Foundation, The Prasanta Banerji Homeopathic Research Foundation). "Here's a study on brain cancer:Int J Oncol. 2003 Oct;23(4):975-82.Ruta 6 selectively induces cell death in brain cancer cells but proliferation in normal peripheral blood lymphocytes: A novel treatment for human brain cancer.Pathak S1, Multani AS, Banerji P, Banerji P.Author informationAbstractAlthough conventional chemotherapies are used to treat patients with malignancies, damage to normal cells is problematic. Blood-forming bone marrow cells are the most adversely affected. It is therefore necessary to find alternative agents that can kill cancer cells but have minimal effects on normal cells. We investigated the brain cancer cell-killing activity of a homeopathic medicine, Ruta, isolated from a plant, Ruta graveolens. We treated human brain cancer and HL-60 leukemia cells, normal B-lymphoid cells, and murine melanoma cells in vitro with different concentrations of Ruta in combination with Ca3(PO4)2. Fifteen patients diagnosed with intracranial tumors were treated with Ruta 6 and Ca3(PO4)2. Of these 15 patients, 6 of the 7 glioma patients showed complete regression of tumors. Normal human blood lymphocytes, B-lymphoid cells, and brain cancer cells treated with Ruta in vitro were examined for telomere dynamics, mitotic catastrophe, and apoptosis to understand the possible mechanism of cell-killing, using conventional and molecular cytogenetic techniques. Both in vivo and in vitro results showed induction of survival-signaling pathways in normal lymphocytes and induction of death-signaling pathways in brain cancer cells. Cancer cell death was initiated by telomere erosion and completed through mitotic catastrophe events. We propose that Ruta in combination with Ca3(PO4)2 could be used for effective treatment of brain cancers, particularly glioma.